Access the full text.
Sign up today, get DeepDyve free for 14 days.
Steven Prideaux, Emma O'Brien, T. Chevassut (2014)
The Genetic Architecture of Multiple MyelomaAdvances in Hematology, 2014
E. Katodritou, S. Papadaki, P. Konstantinidou, E. Terpos (2016)
Is it possible to cure myeloma without allogeneic transplantation?Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 54 1
O. Cope, S. Wyman (1948)
Multiple myeloma.The New England journal of medicine, 239 10
Nisha Joseph, M. Dhodapkar, S. Lonial (2020)
The Role of Early Intervention in High-Risk Smoldering Myeloma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40
L. Melton, S. Rajkumar, S. Khosla, S. Achenbach, A. Oberg, R. Kyle (2003)
Fracture Risk in Monoclonal Gammopathy of Undetermined SignificanceJournal of Bone and Mineral Research, 19
S. Rajkumar, Robert Kyle, Terry Therneau, L. Melton, A. Bradwell, R. Clark, Dirk Larson, M. Plevak, A. Dispenzieri, J. Katzmann (2005)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.Blood, 106 3
R. Kyle, P. Greipp (1980)
Smoldering multiple myeloma.The New England journal of medicine, 302 24
N. Leung, F. Bridoux, C. Hutchison, S. Nasr, P. Cockwell, J. Fermand, A. Dispenzieri, K. Song, R. Kyle (2012)
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.Blood, 120 22
M. Chapman, M. Lawrence, J. Keats, K. Cibulskis, C. Sougnez, Anna Schinzel, C. Harview, Jean-Philippe Brunet, G. Ahmann, Mazhar Adli, K. Anderson, K. Ardlie, D. Auclair, A. Baker, P. Bergsagel, B. Bernstein, Y. Drier, R. Fonseca, S. Gabriel, C. Hofmeister, S. Jagannath, A. Jakubowiak, A. Krishnan, J. Levy, T. Liefeld, S. Lonial, Scott Mahan, Bunmi Mfuko, S. Monti, L. Perkins, R. Onofrio, Trevor Pugh, S. Rajkumar, A. Ramos, D. Siegel, A. Sivachenko, S. Trudel, R. Vij, Douglas Voet, W. Winckler, T. Zimmerman, J. Carpten, Jeff Trent, W. Hahn, L. Garraway, M. Meyerson, E. Lander, G. Getz, T. Golub (2011)
Initial genome sequencing and analysis of multiple myelomaNature, 471
R. Kyle, T. Therneau, S. Rajkumar, D. Larson, M. Plevak, L. Melton (2004)
Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.Mayo Clinic proceedings, 79 7
W. Kuehl, P. Bergsagel (2005)
Early genetic events provide the basis for a clinical classification of multiple myeloma.Hematology. American Society of Hematology. Education Program
P. Neri, N. Bahlis, S. Lonial (2016)
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple MyelomaClinical Cancer Research, 22
O. Landgren (2013)
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.Hematology. American Society of Hematology. Education Program, 2013
P. Watanaboonyongcharoen, T. Nakorn, P. Rojnuckarin, P. Lawasut, T. Intragumtornchai (2012)
Prevalence of monoclonal gammopathy of undetermined significance in ThailandInternational Journal of Hematology, 95
O. Landgren, R. Kyle, R. Pfeiffer, J. Katzmann, N. Caporaso, R. Hayes, A. Dispenzieri, Shaji Kumar, R. Clark, D. Baris, R. Hoover, S. Rajkumar (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.Blood, 113 22
R. Kyle, S. Rajkumar (2010)
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaCurrent Hematologic Malignancy Reports, 5
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
I. Ghobrial, Calixto Cruz, A. Garfall, N. Shah, N. Munshi, J. Kaufman, L. Boise, G. Morgan, V. Adalsteinsson, S. Manier, R. Pillai, F. Malavasi, S. Lonial (2019)
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.Clinical lymphoma, myeloma & leukemia
S. Rajkumar, M. Gertz, M. Lacy, A. Dispenzieri, R. Fonseca, S. Geyer, N. Iturria, Santhosh Kumar, J. Lust, R. Kyle, P. Greipp, T. Witzig (2003)
Thalidomide as initial therapy for early-stage myelomaLeukemia, 17
O. Landgren, B. Graubard, S. Kumar, R. Kyle, J. Katzmann, K. Murata, R. Costello, A. Dispenzieri, N. Caporaso, S. Mailankody, N. Korde, M. Hultcrantz, T. Therneau, D. Larson, J. Cerhan, S. Rajkumar (2017)
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination SurveyBlood Cancer Journal, 7
T. Witzig, K. Laumann, M. Lacy, S. Hayman, A. Dispenzieri, Shaji Kumar, C. Reeder, V. Roy, J. Lust, M. Gertz, P. Greipp, H. Hassoun, S. Mandrekar, S. Rajkumar (2013)
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myelomaLeukemia, 27
Niels Donk, A. Palumbo, H. Johnsen, M. Engelhardt, F. Gay, H. Gregersen, R. Hájek, M. Kleber, H. Ludwig, G. Morgan, P. Musto, T. Plesner, O. Sezer, E. Terpos, A. Waage, S. Zweegman, H. Einsele, P. Sonneveld, H. Lokhorst (2014)
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma NetworkHaematologica, 99
Shivani Seth, S. Zanwar, L. Vu, P. Kapoor (2020)
Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future ProspectsCurrent Hematologic Malignancy Reports, 15
K. Neben, A. Jauch, T. Hielscher, J. Hillengass, N. Lehners, A. Seckinger, M. Granzow, M. Raab, A. Ho, H. Goldschmidt, D. Hose (2013)
Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 34
B. Weiss, J. Abadie, P. Verma, R. Howard, W. Kuehl (2009)
A monoclonal gammopathy precedes multiple myeloma in most patients.Blood, 113 22
O. Lomas, I. Ghobrial (2020)
Clinical Controversies in the Management of Smoldering Multiple Myeloma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40
Elizabeth Hill, Alexander Dew, D. Kazandjian (2019)
State of the science in smoldering myeloma: Should we be treating in the clinic?Seminars in oncology
A. Brioli, Lorenzo Melchor, M. Cavo, G. Morgan (2014)
The impact of intra‐clonal heterogeneity on the treatment of multiple myelomaBritish Journal of Haematology, 165
J. Egan, C. Shi, W. Tembe, Alexis Christoforides, Ahmet Kurdoglu, Shripad Sinari, S. Middha, Y. Asmann, Jessica Schmidt, E. Braggio, J. Keats, R. Fonseca, P. Bergsagel, David Craig, J. Carpten, A. Stewart (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.Blood, 120 5
J. Hillengass, K. Fechtner, M. Weber, T. Bäuerle, S. Ayyaz, C. Heiss, T. Hielscher, T. Moehler, G. Egerer, K. Neben, A. Ho, H. Kauczor, S. Delorme, H. Goldschmidt (2010)
Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 9
O. Lomas, T. Mouhieddine, S. Tahri, I. Ghobrial (2020)
Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after AllCancers, 12
A. Dispenzieri, R. Kyle, J. Katzmann, T. Therneau, D. Larson, J. Benson, R. Clark, L. Melton, M. Gertz, Shaji Kumar, R. Fonseca, D. Jelinek, S. Rajkumar (2008)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.Blood, 111 2
S. Rajkumar, M. Dimopoulos, A. Palumbo, J. Bladé, G. Merlini, M. Mateos, Shaji Kumar, J. Hillengass, E. Kastritis, P. Richardson, O. Landgren, B. Paiva, A. Dispenzieri, B. Weiss, X. Leleu, S. Zweegman, S. Lonial, L. Rosiñol, E. Zamagni, S. Jagannath, O. Sezer, S. Kristinsson, J. Caers, S. Usmani, J. Lahuerta, H. Johnsen, M. Beksaç, M. Cavo, H. Goldschmidt, E. Terpos, R. Kyle, K. Anderson, B. Durie, J. Miguel (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.The Lancet. Oncology, 15 12
M. Mateos, O. Landgren (2016)
MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.Cancer treatment and research, 169
S. Lonial, S. Jacobus, R. Fonseca, M. Weiss, Shaji Kumar, R. Orlowski, J. Kaufman, A. Yacoub, F. Buadi, T. O'brien, J. Matous, Daniel Anderson, R. Emmons, A. Mahindra, L. Wagner, M. Dhodapkar, S. Rajkumar (2020)
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
R. Laar, P. Farmer, R. Bender, A. Zielinski, Kenton Leigh, Nathan Brown, B. Barlogie, G. Morgan (2016)
The 70-Gene MyPRSR prognostic Risk Score Signature Predicts Increased Risk of Progression from MGUS to Multiple Myeloma Requring TreatmentBlood, 128
A. Ravindran, A. Bartley, S. Holton, W. Gonsalves, P. Kapoor, M. Siddiqui, S. Hashmi, A. Marshall, A. Ashrani, A. Dispenzieri, R. Kyle, S. Rajkumar, R. Go (2016)
Prevalence, incidence and survival of smoldering multiple myeloma in the United StatesBlood Cancer Journal, 6
S. Rutella, F. Locatelli (2012)
Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy OutcomesClinical and Developmental Immunology, 2012
J. Keats, M. Chesi, J. Egan, Victoria Garbitt, Stephen Palmer, E. Braggio, S. Wier, P. Blackburn, A. Baker, A. Dispenzieri, Shaji Kumar, S. Rajkumar, J. Carpten, M. Barrett, R. Fonseca, A. Stewart, P. Bergsagel (2012)
Clonal competition with alternating dominance in multiple myeloma.Blood, 120 5
R. Kyle, S. Rajkumar (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 23
K. Anderson, C. Lutz, F. Delft, C. Bateman, Yanping Guo, S. Colman, H. Kempski, A. Moorman, I. Titley, J. Swansbury, L. Kearney, T. Enver, M. Greaves (2011)
Genetic variegation of clonal architecture and propagating cells in leukaemiaNature, 469
P. Schütt, D. Brandhorst, W. Stellberg, Miriam Poser, P. Ebeling, Siemke Müller, U. Buttkereit, B. Opalka, M. Lindemann, H. Grosse-wilde, S. Seeber, T. Moritz, M. Nowrousian (2006)
Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infectionsLeukemia & Lymphoma, 47
D. Kazandjian, S. Mailankody, N. Korde, O. Landgren (2014)
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.Clinical advances in hematology & oncology : H&O, 12 9
R. Kyle, D. Larson, T. Therneau, A. Dispenzieri, Shaji Kumar, J. Cerhan, V. Rajkumar (2018)
Long‐Term Follow‐up of Monoclonal Gammopathy of Undetermined SignificanceThe New England Journal of Medicine, 378
O. Landgren, J. Hofmann, C. McShane, L. Santo, M. Hultcrantz, N. Korde, S. Mailankody, D. Kazandjian, K. Murata, K. Thoren, L. Ramanathan, A. Dogan, E. Rustad, Sydney Lu, T. Akhlaghi, S. Kristinsson, M. Björkholm, S. Devlin, M. Purdue, R. Pfeiffer, I. Turesson (2019)
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.JAMA oncology
D. Kazandjian (2016)
Multiple myeloma epidemiology and survival: A unique malignancy.Seminars in oncology, 43 6
E. Pérez‐Persona, G. Mateo, R. García-Sanz, M. Mateos, N. Heras, Alfonso Coca, J. Hernández, J. Galende, G. Martín‐Nuñez, A. Bárez, J. Alonso, Alejandro Martín, C. López-Berges, A. Órfão, J. Miguel, M. Vidriales (2010)
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cellsBritish Journal of Haematology, 148
I. Turesson, R. Vélez, S. Kristinsson, O. Landgren (2010)
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 5
S. Vincent, Rajkumar Myeloma, MD Anderson, MD Rajkumar, MD Bergsagel, MD Reece, Mayo Clinic (2005)
MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.Hematology. American Society of Hematology. Education Program
R. Siegel, K. Miller, A. Jemal (2016)
Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 66
E. Pérez‐Persona, M. Vidriales, G. Mateo, R. García-Sanz, M. Mateos, Alfonso Coca, J. Galende, G. Martín‐Nuñez, J. Alonso, N. Heras, J. Hernández, Alejandro Martín, C. López-Berges, A. Órfão, J. Miguel (2007)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.Blood, 110 7
B. Barlogie, F. Rhee, J. Shaughnessy, J. Epstein, S. Yaccoby, M. Pineda‐Roman, K. Hollmig, Y. Alsayed, A. Hoering, J. Szymonifka, E. Anaissie, N. Petty, N. Kumar, G. Srivastava, Bonnie Jenkins, J. Crowley, J. Zeldis (2008)
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease.Blood, 112 8
H. Gregersen, J. Ibsen, Lene Mellemkjœr, J. Dahlerup, J. Olsen, H. Sørensen (2001)
Mortality and causes of death in patients with monoclonal gammopathy of undetermined significanceBritish Journal of Haematology, 112
L. Mikkilineni, J. Kochenderfer (2017)
Chimeric antigen receptor T-cell therapies for multiple myeloma.Blood, 130 24
F. Maura, N. Bolli, E. Rustad, M. Hultcrantz, N. Munshi, O. Landgren (2019)
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.JAMA oncology
J. Bida, R. Kyle, T. Therneau, L. Melton, M. Plevak, D. Larson, A. Dispenzieri, J. Katzmann, S. Rajkumar (2009)
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients.Mayo Clinic proceedings, 84 8
S. Rajkumar (2018)
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 93
T. Sergentanis, F. Zagouri, G. Tsilimidos, Anastasia Tsagianni, Melina Tseliou, M. Dimopoulos, T. Psaltopoulou (2015)
Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses.Clinical lymphoma, myeloma & leukemia, 15 10
A. Rajan, S. Rajkumar (2013)
Diagnostic evaluation of monoclonal gammopathy of undetermined significanceEuropean Journal of Haematology, 91
J. Hillengass, K. Kilk, Karin Listl, T. Hielscher, K. Neben, D. Hose, M. Weber, A. Ho, H. Goldschmidt, O. Landgren (2012)
Over 30% of Smoldering Myeloma Patients Have Tumor Cell Bone Marrow Infiltration Patterns Similar to Multiple Myeloma: A Large (n=544) Clinical Study Using Whole-Body MRI.Blood, 120
D. Alexander, P. Mink, H. Adami, P. Cole, J. Mandel, M. Oken, D. Trichopoulos (2007)
Multiple myeloma: A review of the epidemiologic literatureInternational Journal of Cancer, 120
A. Ray, Deepika Das, Yan Song, P. Richardson, Nikhil Munshi, D. Chauhan, K. Anderson (2015)
Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cellsLeukemia, 29
A. Lakshman, S. Rajkumar, F. Buadi, M. Binder, M. Gertz, M. Lacy, A. Dispenzieri, D. Dingli, A. Fonder, S. Hayman, M. Hobbs, W. Gonsalves, Y. Hwa, P. Kapoor, N. Leung, R. Go, Yi Lin, T. Kourelis, R. Warsame, J. Lust, S. Russell, S. Zeldenrust, R. Kyle, Shaji Kumar (2018)
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteriaBlood Cancer Journal, 8
B. Koppula, Justin Kaptuch, Christopher Hanrahan (2013)
Imaging of multiple myeloma: usefulness of MRI and PET/CT.Seminars in ultrasound, CT, and MR, 34 6
R. Kyle, B. Durie, S. Rajkumar, O. Landgren, J. Bladé, G. Merlini, N. Kröger, H. Einsele, D. Vesole, M. Dimopoulos, J. Miguel, H. Avet-Loiseau, R. Hájek, Wenming Chen, K. Anderson, H. Ludwig, P. Sonneveld, S. Pavlovsky, A. Palumbo, P. Richardson, B. Barlogie, P. Greipp, R. Vescio, I. Turesson, J. Westin, M. Boccadoro (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia, 24
C. Cesana, C. Klersy, L. Barbarano, A. Nosari, M. Crugnola, E. Pungolino, L. Gargantini, S. Granata, M. Valentini, E. Morra (2002)
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 6
H. Gregersen, K. Madsen, H. Sørensen, H. Schønheyder, J. Ibsen, J. Dahlerup (1998)
The risk of bacteremia in patients with monoclonal gammopathy of undetermined significanceEuropean Journal of Haematology, 61
M. Dhodapkar (2016)
MGUS to myeloma: a mysterious gammopathy of underexplored significance.Blood, 128 23
J. Pepe, M. Petrucci, M. Mascia, S. Piemonte, V. Fassino, E. Romagnoli, S. Minisola (2008)
The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined SignificanceCalcified Tissue International, 82
R. Kyle, E. Remstein, T. Therneau, A. Dispenzieri, Paul Kurtin, J. Hodnefield, D. Larson, M. Plevak, D. Jelinek, R. Fonseca, L. Melton, S. Rajkumar (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.The New England journal of medicine, 356 25
R. Kyle, S. Rajkumar (2007)
Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progressionBritish Journal of Haematology, 139
J. Bladé (2004)
On the "significance" of monoclonal gammopathy of undetermined significance.Mayo Clinic proceedings, 79 7
M. Hjorth, Louise Hellquist, E. Holmberg, B. Magnusson, S. Rödjer, J. Westin (1993)
Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I — A randomized studyEuropean Journal of Haematology, 50
M. Mateos, J. Martínez-López, P. Otero, E. Ocio, M. González, A. Oriol, N. Gutiérrez, B. Paiva, R. Ríos, L. Rosiñol, Miguel Alvarez, M. Calasanz, J. Bargay, A. Gonzalez, A. Alegre, F. Escalante, R. Martínez, N. Puig, J. Rubia, A. Teruel, M. Cedena, F. Arriba, L. Palomera, M. Hernandez, J. Jiménez, Jesús Martín, Esther Piensa, A. Mateo, V. Calle, J. Bladé, J. Lahuerta, J. San-Miguel (2018)
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with RdBlood
J. Bladé, A. López-Guillermo, C. Rozman, F. Cervantes, C. Salgado, J. Aguilar, J. Vives‐Corrons, E. Montserrat (1992)
Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significanceBritish Journal of Haematology, 81
Robert Kyle, M. Gertz, T. Witzig, J. Lust, M. Lacy, A. Dispenzieri, R. Fonseca, S. Rajkumar, J. Offord, Dirk Larson, Matthew Plevak, Terry Therneau, P. Greipp (2003)
Review of 1027 patients with newly diagnosed multiple myeloma.Mayo Clinic proceedings, 78 1
O. Landgren, R. Kyle, Vincent Rajkumar (2011)
From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early InterventionClinical Cancer Research, 17
D. Chauhan, Ajita Singh, M. Brahmandam, Ruben Carrasco, Madhavi Bandi, T. Hideshima, G. Bianchi, K. Podar, Y. Tai, C. Mitsiades, N. Raje, D. Jaye, Shaji Kumar, P. Richardson, N. Munshi, K. Anderson (2009)
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer cell, 16 4
M. Dhodapkar, R. Sexton, S. Waheed, S. Usmani, X. Papanikolaou, B. Nair, N. Petty, J. Shaughnessy, A. Hoering, J. Crowley, R. Orlowski, B. Barlogie (2014)
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).Blood, 123 1
N. Biran, D. Vesole, M. Donato, A. Ip, G. Kaur, S. Goldberg, D. Siegel (2020)
Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
K. Mahnke, S. Ring, T. Johnson, S. Schallenberg, K. Schönfeld, Volker Storn, T. Bedke, A. Enk (2007)
Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: Role of B7‐H3 expression and antigen presentationEuropean Journal of Immunology, 37
O. Landgren, R. Zeig-Owens, Orsolya Giricz, D. Goldfarb, K. Murata, K. Thoren, L. Ramanathan, M. Hultcrantz, A. Dogan, G. Nwankwo, U. Steidl, K. Pradhan, C. Hall, H. Cohen, N. Jaber, T. Schwartz, L. Crowley, M. Crane, S. Irby, M. Webber, A. Verma, D. Prezant (2018)
Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center DisasterJAMA Oncology, 4
L. Baldini, A. Guffanti, Bruno Cesana, M. Colombi, O. Chiorboli, Isabella Damilano, A. Maiolo (1996)
Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.Blood, 87 3
(2020)
Int Myeloma Found
O. Landgren (2017)
Shall we treat smoldering multiple myeloma in the near future?Hematology. American Society of Hematology. Education Program, 2017 1
M. Mateos, M. Hernandez, P. Giraldo, J. Rubia, F. Arriba, L. Corral, L. Rosiñol, B. Paiva, L. Palomera, J. Bargay, A. Oriol, F. Prósper, Javier López, E. Olavarría, N. Quintana, J. García, J. Bladé, J. Lahuerta, J. Miguel (2013)
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.The New England journal of medicine, 369 5
S. Kristinsson, M. Björkholm, T. Andersson, S. Eloranta, P. Dickman, L. Goldin, C. Blimark, U. Mellqvist, A. Wåhlin, I. Turesson, O. Landgren (2009)
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based studyHaematologica, 94
E. Mena, P. Choyke, Esther Tan, O. Landgren, K. Kurdziel (2011)
Molecular imaging in myeloma precursor disease.Seminars in hematology, 48 1
R. Kyle (1978)
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.The American journal of medicine, 64 5
R. Kyle, J. Child, K. Anderson, B. Barlogie, R. Bataille, W. Bensinger, J. Bladé, M. Boccadoro, W. Dalton, M. Dimopoulos, B. Djulbegovic, M. Drayson, B. Durie, T. Facon, R. Fonseca, G. Gahrton, P. Greipp, J. Harousseau, D. Harrington, M. Hussein, D. Joshua, H. Ludwig, G. Morgan, M. Oken, R. Powles, P. Richardson, D. Roodman, J. Miguel, K. Shimizu, C. Shustik, B. Sirohi, P. Sonneveld, G. Tricot, I. Turesson, B. Ness, D. Vesole, D. Weber, J. Westin, K. Wheatley (2003)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working GroupBritish Journal of Haematology, 121
T. Therneau, R. Kyle, L. Melton, D. Larson, J. Benson, C. Colby, A. Dispenzieri, Shaji Kumar, J. Katzmann, J. Cerhan, S. Rajkumar (2012)
Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.Mayo Clinic proceedings, 87 11
N. Haradhvala, O. Zavidij, T. Mouhieddine, Romanos Sklavenitis-Pistofidis, Jihye Park, M. Reidy, A. Flaifel, Ben Ferland, S. Manier, M. Bustoros, D. Huynh, M. Capelletti, Brianna Berrios, M. Rahmat, Chia-Jen Liu, M. He, E. Braggio, R. Fonseca, Y. Maruvka, Jennifer Guerriero, Melissa Goldman, E. Allen, S. Mccarroll, J. Azzi, G. Getz, I. Ghobrial (2019)
Abstract 139: Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myelomaTumor Biology
N. Bolli, F. Maura, S. Minvielle, Dominik Gloznik, R. Szalat, A. Fullam, I. Martincorena, K. Dawson, M. Samur, J. Zamora, P. Tarpey, H. Davies, M. Fulciniti, M. Shammas, Y. Tai, F. Magrangeas, P. Moreau, P. Corradini, K. Anderson, L. Alexandrov, D. Wedge, H. Avet-Loiseau, P. Campbell, N. Munshi (2018)
Genomic patterns of progression in smoldering multiple myelomaNature Communications, 9
R. Kyle, Terry Therneau, S. Rajkumar, Dirk Larson, M. Plevak, J. Offord, A. Dispenzieri, J. Katzmann, L. Joseph, Melton Iii, Biostatistics, Immunology, Epidemiology, Mayo Clinic, Minn Rochester (2006)
Prevalence of monoclonal gammopathy of undetermined significance.The New England journal of medicine, 354 13
AbstractMonoclonal gammopathy of undetermined significance (MGUS) is a clonal plasma cell disorder implicated as a precursor of multiple myeloma (MM), while smoldering multiple myeloma (SMM) is a malignant plasma cell disorder without evidence of a myeloma-defining event(s) (MDE). This is a review article of both disorders outlining their current definition and management according to the current standard of care. We focus on the pathogenesis of MM and the role of MGUS and SMM in the development of active MM. MGUS is a benign disorder and, subsequently, is followed by observation. In contrast, for SMM, although the current standard of care is “watch and wait”, this paper will explore the circumstances in which treatment should be considered to prevent MDE.
Acta Haematologica Polonica – de Gruyter
Published: Dec 1, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.